Cambridge, United Kingdom (August 27th, 2010) – Novus Biologicals, a leading international supplier of high quality antibodies and proteins to the bioresearch industry, is pleased to announce the introduction of a new range of Beta Amyloid antibodies to their antibody catalogue. Playing a pivotal role in Alzheimer’s Disease research, of particular interest are two pyroglutamate forms targeted to different N-terminal E-start points.
As well as Beta Amyloid antibody (NBP1-44047), the antibodies Novus Biologicals have released include Beta Amyloid [pyroglutamate3] antibody (NBP1-44048), and Beta Amyloid [pyroglutamate11] Antibody (NBP1-44070), which are targeted at the N-terminus 3-pyro and N-terminus 11-pyro E start points, respectively. The company also supplies the relative blocking peptides (NBP1-44964, NBP1-44969 and NBP1-44975).
Alzheimer’s disease is characterised by the formation of cerebral and vascular plaques. These are caused by an excess build-up of beta Amyloid (Abeta) peptides in the brain, something that was first noted in 1991. Recently, it was reported that N-truncated peptides undergoing pyroglutamic acid synthesis at positions 3 and 11 – predominantly 3 – are a major component of plaque formation in Alzheimer’s patients. These modified peptides are more hydrophobic, more resistant to degradation, more prone to aggregation and – in some cases – more toxic than the non-truncated form. Studies are therefore now focussed on the molecular pathways leading to the formation of truncated beta Amyloid 3 and 11 peptides, for which the three new antibodies released by Novus will prove invaluable. Scientists are hopeful this will eventually lead to the development of immunotherapies effective against Alzheimer’s Disease. Vaccines so far developed mainly target the N-terminal epitope of the full-length protein; this epitope is absent from the truncated forms.
Dr. Mark Parker, senior scientist and head of product development for Novus, explains: “The association between beta amyloid proteins and Alzheimer’s has been known since the 1990s, but it is only since the discovery of these N-truncated forms that real advancements have been made. Our new Abeta and beta Amyloid pyroglutamate antibodies target all three major proteins currently being studied by Alzheimer’s Disease researchers, and come with a 100% guarantee of quality and effectiveness.”
For more details about Novus Biologicals, please visit their website at http://www.novusbio.com, or call +44 (0)1223 426001 (Europe) or 1-888-50-NOVUS (USA).
About Novus Biologicals:
Novus Biologicals is an international scientific company, helping to accelerate the advancement of scientific discoveries by developing and commercialising new products in scientific and biological fields. By promoting and commercialising unique biological materials and products to the biological research community, Novus plays an important part in helping to advance international biological research practices. Novus is also constantly monitoring emerging scientific trends and strives to supply products for their advancement.
Contact Details:
Novus Biologicals Europe
12 Cambridge Science Park
Cambridge, CB4 0FQ, UK
Tel: +44 (0)1223 426001
Fax: +44 (0)871 971 1635
Email: europe@novusbio.com
Novus Biologicals Worldwide
PO Box 802
Littleton, CO 80160 USA
Tel: 1-888-50-NOVUS
Fax: 303-730-1966
Email: novus@novusbio.com
